Are new cancer drugs been developed and recommended to patients?

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? The Institute of Cancer Research, London, one of the world’s most influential cancer research organisations, has published an in-depth analysis about the discovery and access of innovative cancer drugs. Read the full report Haematological cancers have seen dramatic […]

Read full story

A New Edition of the MDS Patient Handbook is out!

Being diagnosed with myelodysplastic syndrome (MDS) can be a shock, particularly when you may never have heard of it. MDS UK has now produced a new edition of the MDS patient booklet, created in cooperation with our colleagues from Leukaemia Care and Bloodwise. At MDS UK, we felt there was an urgent need to revise the […]

Read full story

Vidaza / Azacitidine: Know more about this drug

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Vidaza and Azacitidine are the same drug Azacitidine is the official generic and non-proprietary name given to the drug active ingredient while Vidaza is its trade name. The drug is widely available in the UK for the treatment […]

Read full story

What is CAR-T cell therapy? Learn how this immunotherapy works in blood cancer

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Cell therapies, sometimes called “living therapies”, are an especially promising and rapidly growing area of cancer research. One approach that’s been pioneered by Memorial Sloan Kettering researchers, led by investigator Michel Sadelain, is called CAR-T cell immunotherapy. This […]

Read full story

MDS UK grows its team to increase its support to patients

The MDS UK Committee is pleased to welcome two new members to the charity team: Lizzie Marshall, and Chris Fryer. Both Lizzie and Chris have experience in the Non-Profit and Charity Sector. Lizzie is a trainee psychotherapist with a background in the performing arts. She works supporting vulnerable people with learning difficulties alongside her new […]

Read full story

PANTHER: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Higher risk MDS, CMML, low blast count AML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Azacitidine, Pevonedistat
Read full story

BRIGHT: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Glasdegib, Azacitidine
Read full story

FT-2102: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS: Patients with Acute Myeloid Leukaemia or Myelodysplastic Syndrome with an IDH1 R132 mutation
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: FT-2102
Read full story
Free donations by shopping